Astellas Pharma Inc. (ALPMY)
USD 9.54
(-1.14%)
USD 9.54
(-1.14%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 | 670.02 Billion JPY | 430.44% |
| 2023 | -176.83 Billion JPY | -71.28% |
| 2022 | -103.24 Billion JPY | -115.7% |
| 2021 | -47.86 Billion JPY | -150.41% |
| 2020 | 94.94 Billion JPY | 130.64% |
| 2019 | -309.87 Billion JPY | 6.21% |
| 2018 | -330.38 Billion JPY | 2.62% |
| 2017 | -339.28 Billion JPY | 5.44% |
| 2016 | -358.8 Billion JPY | 9.33% |
| 2015 | -395.71 Billion JPY | -1.32% |
| 2014 | -390.56 Billion JPY | -47.84% |
| 2013 | -264.17 Billion JPY | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 656.43 Billion JPY | 424.19% |
| 2024 Q1 | -202.48 Billion JPY | -14.51% |
| 2024 Q4 | 670.02 Billion JPY | -6.51% |
| 2024 FY | 670.02 Billion JPY | 478.9% |
| 2024 Q3 | 716.67 Billion JPY | 9.18% |
| 2023 Q3 | -233.07 Billion JPY | 16.36% |
| 2023 Q2 | -278.68 Billion JPY | -38.38% |
| 2023 Q1 | -201.39 Billion JPY | -95.07% |
| 2023 Q4 | -176.83 Billion JPY | 24.13% |
| 2023 FY | -176.83 Billion JPY | -71.28% |
| 2022 Q1 | -100.55 Billion JPY | -110.09% |
| 2022 FY | -103.24 Billion JPY | -115.7% |
| 2022 Q4 | -103.24 Billion JPY | 30.56% |
| 2022 Q2 | -113.45 Billion JPY | -12.83% |
| 2022 Q3 | -148.67 Billion JPY | -31.04% |
| 2021 FY | -47.86 Billion JPY | -150.41% |
| 2021 Q4 | -47.86 Billion JPY | 84.32% |
| 2021 Q3 | -305.26 Billion JPY | -7.49% |
| 2021 Q1 | -237.11 Billion JPY | -396.47% |
| 2021 Q2 | -283.98 Billion JPY | -19.77% |
| 2020 FY | 94.94 Billion JPY | 130.64% |
| 2020 Q1 | -257.82 Billion JPY | 16.49% |
| 2020 Q2 | -308.4 Billion JPY | -19.62% |
| 2020 Q3 | -274.44 Billion JPY | 11.01% |
| 2020 Q4 | 79.97 Billion JPY | 129.14% |
| 2019 Q2 | -302.99 Billion JPY | 1.06% |
| 2019 FY | -309.87 Billion JPY | 6.21% |
| 2019 Q4 | -308.73 Billion JPY | 6.37% |
| 2019 Q3 | -329.72 Billion JPY | -8.82% |
| 2019 Q1 | -306.23 Billion JPY | 6.44% |
| 2018 Q3 | -327.92 Billion JPY | -7.81% |
| 2018 FY | -330.38 Billion JPY | 2.62% |
| 2018 Q4 | -327.31 Billion JPY | 0.19% |
| 2018 Q2 | -304.16 Billion JPY | 2.09% |
| 2018 Q1 | -310.64 Billion JPY | 8.46% |
| 2017 Q2 | -365.45 Billion JPY | -17.58% |
| 2017 Q1 | -310.82 Billion JPY | 13.11% |
| 2017 FY | -339.28 Billion JPY | 5.44% |
| 2017 Q4 | -339.34 Billion JPY | 2.44% |
| 2017 Q3 | -347.81 Billion JPY | 4.83% |
| 2016 Q1 | -370.61 Billion JPY | 6.34% |
| 2016 Q3 | -338.74 Billion JPY | 12.33% |
| 2016 Q4 | -357.7 Billion JPY | -5.6% |
| 2016 Q2 | -386.38 Billion JPY | -4.26% |
| 2016 FY | -358.8 Billion JPY | 9.33% |
| 2015 Q2 | -421.27 Billion JPY | -12.96% |
| 2015 Q1 | -372.94 Billion JPY | 4.51% |
| 2015 FY | -395.71 Billion JPY | -1.32% |
| 2015 Q4 | -395.71 Billion JPY | 9.64% |
| 2015 Q3 | -437.91 Billion JPY | -3.95% |
| 2014 Q3 | -303.43 Billion JPY | -17.31% |
| 2014 Q1 | -234.56 Billion JPY | 11.21% |
| 2014 Q2 | -258.65 Billion JPY | -10.27% |
| 2014 FY | -390.56 Billion JPY | -47.84% |
| 2014 Q4 | -390.56 Billion JPY | -28.71% |
| 2013 Q2 | -191.52 Billion JPY | 0.0% |
| 2013 Q3 | -242.96 Billion JPY | -26.86% |
| 2013 Q4 | -264.17 Billion JPY | -8.73% |
| 2013 FY | -264.17 Billion JPY | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| AstraZeneca PLC | 22.74 Billion USD | -2845.204% |
| Bristol-Myers Squibb Company PFD CONV 2 | 30 Billion USD | -2133.43% |
| CSPC Pharmaceutical Group Limited | -1.59 Billion USD | 42133.375% |
| Clarus Therapeutics Holdings, Inc. | 15.85 Million USD | -4226145.742% |
| Novartis AG | 12.95 Billion USD | -5071.972% |
| PT Kalbe Farma Tbk. | -169.7 Million USD | 394927.805% |